All In Biotech

Drug Trial Radar · NCT05222906

Study to Evaluate the Efficacy and Safety of Venglustat in Adult and Pediatric Patients With Gaucher Disease Type 3

A Phase 3, Multicenter, Multinational, Randomized, Double-blind, Double-dummy, Active-comparator Study to Evaluate the Efficacy and Safety of Venglustat in Adult and Pediatric Patients With Gaucher Disease Type 3 (GD3) Who Have Reached Therapeutic Goals With Enzyme Replacement Therapy (ERT)

Last checked: Nov 19, 2026Latest source record: Jul 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

43

Actual

Start

Apr 18, 2022

Primary completion

Oct 2, 2025

Study completion Oct 30, 2026

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
First posted
Feb 3, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a parallel arm, Phase 3, double-blind, double-dummy, active-comparator, 2 arm study to evaluate the efficacy and safety of daily oral venglustat versus intravenous Cerezyme infusions every two weeks for improvement or stabilization of the neurological manifestations and maintenance of systemic disease stability in participants aged ≥12 and \<18 years and adult patients with Gaucher disease Type 3 (GD3) who have been treated with Enzyme Replacement Therapy (ERT) for at least 3 years.

Conditions

  • Gaucher's Disease Type III

Interventions

  • VenglustatDrug

    tablet; oral

  • imigluceraseDrug

    sterile lyophilized product; intravenous

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Scale for Assessment and Rating of Ataxia (SARA) modified total scoreTime frame: From baseline to Week 52
  2. Change in Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) total scale index scoreTime frame: From baseline to Week 52

Locations

22 sites in 11 countries. Site status is shown where the registry gives one.

  • Yale University School of Medicine - Investigational Site Number: 8400003

    New Haven, Connecticut

  • University of Iowa - Investigational Site Number: 8400002

    Iowa City, Iowa

  • Texas Oncology - Medical City Dallas Site Number : 8400008

    Dallas, Texas

  • Lysosomal & Rare Disorders Research & Treatment Center, Inc - Investigational Site Number: 8400001

    Fairfax, Virginia

  • Hospital de Ninos - Investigational Site Number: 320001

    Buenos Aires, Argentina

  • Children's Hospital Research Institute of Manitoba - Investigational Site Number: 1240001

    Winnipeg, Manitoba, Canada

  • Peking Union Medical College Hospital - Investigational Site Number: 1560001

    Beijing, China

  • The First Affiliated Hospital - Investigational Site Number: 1560002

    Guangzhou, China

  • Xinhua Hospital - Investigational Site Number: 1560004

    Shanghai, China

  • National Taiwan University Hospital-Investigational Site Number: 1580001

    Taipei, Taiwan, China

  • 47-87, boulevard de l'hôpital - Investigational Site Number: 2500003

    Paris, France

  • Hopital Necker - Investigational Site Number: 2500001

    Paris, France

  • SphinCS GmbH - Investigational Site Number: 2760001

    Hochheim am Main, Germany

  • Debreceni Egyetem, Klinikai Központ, Reumatológiai Klinika - Investigational Site Number: 3480001

    Debrecen, Hungary

  • Azienda Ospedaliera Universitaria (AOU) "Federico II" - Investigational Site Number: 3800002

    Naples, Italy

  • Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico - Investigational Site Number : 3800003

    Milan, Lombardy, Italy

  • Tohoku University School of Medicine - Investigational Site Number: 3920001

    Sendai, Japan

  • Odawara Municipal Hospital-Investigational Site Number : 3920002

    Odawara, Kanagawa, Japan

  • Cukurova University Medical School Hospital-Investigational Site Number : 7920001

    Adana, Turkey (Türkiye)

  • Gazi University Medical Hospital-Investigational Site Number : 7920002

    Ankara, Turkey (Türkiye)

  • Istanbul University Medical Faculty Hospital-Investigational Site Number : 7920004

    Istanbul, Turkey (Türkiye)

  • Investigational Site Number : 8260001

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.